Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2-breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)

JOURNAL OF CLINICAL ONCOLOGY(2023)

引用 0|浏览14
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要